Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy
Campbell, T.M.; Brown, C.W.
Journal of Drugs in Dermatology Jdd 7(12): 1161-1163
2008
ISSN/ISBN: 1545-9616 PMID: 19137770 Document Number: 12073
The epidermal growth factor receptor (EGFR) inhibitor class of agents have been reported to cause multiple cutaneous adverse events. These drug eruptions are thought by some to indicate a good prognosis. The authors report of a case of a psoriasiform scalp eruption simultaneously occurring with an acneiform or follicular rash in a single patient. To present knowledge, this is the first report of a psoriasiform eruption triggered by erlotinib. In addition, this case report demonstrates 2 completely distinct cutaneous morphologies occurring simultaneously with erlotinib therapy in a single patient.
Document emailed within 1 workday
